Avalon Globocare CORP 8-K filings

Avalon GloboCare Corp. has issued a significant number of unregistered common shares to noteholders through debt conversions and to consultants for services, increasing its total outstanding shares.

Avalon GloboCare Corp. has obtained a waiver from Mast Hill Fund, L.P. to extend the maturity date of its senior secured promissory note to August 31, 2025.

Avalon GloboCare's subsidiary, Q&A Distribution, LLC, has entered into a wholesale distribution agreement with Saga Health Corporation to integrate the KetoAir breathalyzer into its Holistic Health Reset Program for first responders.

Avalon GloboCare Corp. has entered into a securities purchase agreement with Mast Hill Fund, L.P. to sell 300 shares of Series C Convertible Preferred Stock for $300,000, yielding net proceeds of $290,000.

Avalon GloboCare Corp. has completed a private placement, raising $450,500 in net proceeds through the sale of common stock and pre-funded warrants to Brown Stone Capital Ltd., while also issuing shares from a note conversion.

Avalon GloboCare Corp. announced the issuance of a standard patent in Hong Kong for its proprietary CAR-T and CAR-Natural Killer (NK) cell technology, strengthening its global intellectual property portfolio.

Avalon GloboCare Corp. has entered into agreements for two convertible promissory notes totaling $200,000, bearing a significant one-time interest charge and offering conversion into common stock at a fixed price, subject to ownership and exchange limitations.

Avalon GloboCare Corp. has entered into a definitive agreement with Qi Diagnostics Limited to co-develop a volatile organic compound (VOC) nanosensor-based cannabis breathalyzer aimed at real-time detection of impaired driving.

Avalon GloboCare Corp. announced a new $500,000 equity investment from York Sun Investment Holding Limited and secured a waiver of potential cash penalties on a senior secured promissory note, while also amending the beneficial ownership limitation for its Series C Convertible Preferred Stock.

Avalon GloboCare Corp. has received a notice from Nasdaq indicating non-compliance with the minimum stockholders' equity requirement, potentially leading to delisting if a compliance plan is not accepted.

Avalon GloboCare and YOOV Group have jointly announced the filing of a registration statement for their proposed merger, aiming to create a publicly-traded company focused on AI-driven business automation.

Avalon GloboCare's KetoAir breathalyzer will be used in partnership with SpecialtyHealth, Inc. to support the BrAce 4 Impact Challenge, a fitness initiative for police chiefs.

Avalon GloboCare has been granted a patent in China for its innovative CAR-T and CAR-NK cell technology, marking a significant milestone in its global intellectual property strategy.

Avalon GloboCare partners with Pounds Transformation Clinics to launch the BrAce 4 Impact Challenge Series, integrating KetoAir breathalyzers into weight management programs.

Avalon GloboCare will merge with YOOV Group Holding, a business AI automation solutions provider, in a deal expected to close in the third quarter of 2025, pending stockholder and regulatory approvals.

Avalon GloboCare Corp. has redeemed its 40% equity interest in Laboratory Services MSO for $1.745 million, to be paid in installments, and SCBC Holdings LLC surrendered its Series B Convertible Preferred Stock in Avalon.

Avalon GloboCare has secured a Notice of Allowance from China for its AVAR1901CN patent, enhancing its global intellectual property portfolio in CAR-T and CAR-NK cell therapies.

Avalon GloboCare Corp. finalized an exchange agreement with its Chairman, Wenzhao Lu, involving preferred stock, and filed the designation for its Series D Convertible Preferred Stock.

Avalon GloboCare Corp. has entered into a securities purchase agreement to sell up to 7,000 shares of Series C Convertible Preferred Stock for a total of $7 million to York Sun Investment Holding Limited.

Avalon GloboCare Corp. has entered into an agreement to waive debt amortization payments, issue a warrant, and create a new series of convertible preferred stock.

Avalon GloboCare has successfully regained compliance with Nasdaq's minimum bid price requirement, avoiding potential delisting.

Avalon GloboCare has launched an affiliate marketing program called 'BrAce for Impact' to promote its KetoAir breathalyzer device.

Avalon GloboCare Corp. received a delisting notice from Nasdaq after failing to regain compliance with the minimum bid price requirement despite a recent reverse stock split.

Avalon GloboCare has appointed Dr. Charles Cavo to its Scientific Advisory Board to support the marketing and business development of KetoAir, a handheld breathalyzer for ketogenic health.

Avalon GloboCare Corp. has executed a 1-for-15 reverse stock split and reduced its authorized shares from 490 million to 100 million, effective October 25, 2024.

Avalon GloboCare has signed a memorandum of understanding with Qi Diagnostics to explore the co-development of a real-time cannabis breathalyzer.

Avalon GloboCare Corp. will implement a 1-for-15 reverse stock split on October 28, 2024, to meet Nasdaq's minimum bid price requirement.

Avalon GloboCare Corp. held its 2024 annual meeting, where stockholders voted on key proposals including the election of directors, ratification of the auditor, and approval of a reverse stock split.

Avalon GloboCare will sponsor the Keto Pa-LOU-za 2024 Conference to showcase and sell their KetoAir breathalyzer device.

Avalon GloboCare's partner, Laboratory Services MSO, is set to launch sales of the FDA-registered GeeWhiz External Condom Catheter in Q3 2024, targeting the growing male urinary incontinence market.